

July 1, 2011

**ONO PHARMACEUTICAL CO., LTD.**

President and Representative Director: Gyo Sagara,  
Code No.: 4528 at the 1<sup>st</sup> section of the Tokyo / Osaka Stock Exchange  
INQUIRIES: Kinya Morimoto, Executive Officer, Director, Corporate Communications

**Approval for Corebeta<sup>®</sup> for Injection 12.5mg for Improvement of Image Quality  
in Coronary CT Angiography in Japan**

Ono Pharmaceutical Co., Ltd. announced today that an application for Corebeta<sup>®</sup> for Injection 12.5mg for Injection (INN: landiolol) for improvement of image quality of coronary computed tomographic (CT) angiography was approved in July 1, 2011 in Japan. This is the first drug to improve image quality of CT angiography in Japan.

Coronary angiography with CT has recently attracted attention as a method diagnosing severity of coronary stenosis in patients with ischemic cardiac diseases such as angina and acute myocardial infarction. Unlike coronary angiography with cardiac catheter, the test is less invasive without requiring arterial puncture. It is also simple and convenient because it can be done on an outpatient basis within a relatively short period of time. However the test often causes increase in heart rate and provides low quality of imaging making a correct diagnosis difficult, and therefore it is necessary to reduce their heart rate only during such short period of time for the performance of the test.

Corebeta<sup>®</sup> is selectively blocking beta-1 receptors mainly located in the heart, is expected to provide clearer image in coronary angiography with CT by swiftly reducing heart rate in patients with increased heart rate.

Corebeta<sup>®</sup> contains an identical drug substance to Onoact<sup>®</sup> 50 for Injection. The drug is a short-acting selective beta-1 blocker discovered and developed by Ono, and was approved for the emergency treatment for intraoperative tachyarrhythmia (atrial fibrillation and flutter and, sinus tachycardia) in Japan in July 2002. Additionally it was also approved for post-operative tachyarrhythmia (atrial fibrillation and flutter, and sinus tachycardia) with monitoring of circulatory dynamics in October 2006. The drug has been administered to a large number of patients since the first approval.

## PRODUCT SUMMARY

Product name: Corebeta<sup>®</sup> for Injection 12.5mg

Generic name: Landiolol Hydrochloride

Indication: Improvement of image quality of coronary arteries for coronary computed tomographic (CT) angiography in patients with increased heart rate

Dosage regimen 0.125mg per kg of Landiolol Hydrochlorid is administered by intravenous injection in one minute.